Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial assessing safety and activity of erlotinib plus bevacizumab for recurrent or refractory non-small-cell lung cance...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Herbst, Roy S, Ansari, Rafat, Bustin, Frederique, Flynn, Patrick, Hart, Lowell, Otterson, Gregory A, Vlahovic, Gordana, Soh, Chang-Heok, O’Connor, Paula, Hainsworth, John
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2011
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134127/
https://ncbi.nlm.nih.gov/pubmed/21621716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(11)60545-X
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak